Loading company…
Prothea Technologies develops medical technology for lung cancer imaging, biopsy and treatment.
Prothea designs solutions intended to combine lung cancer procedures into a single hospital visit for healthcare providers. The company is based in Edinburgh, UK. In April 2024, it raised EUR 12 million in Series A funding co-led by Earlybird Venture Capital and Merieux Equity Partners to support clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in